The gut microbiota, consisting of bacteria, fungi, archaea, viruses, and protozoa, together with their collective genomes (microbiome), plays a key role in immune system development and maturation, gut morphology, and in performing essential metabolic functions. Several factors, including lifestyle, body mass index, diet, antibiotic use, and the environment, influence the balance of the intestinal microbiota, whose alterations (the so-called dysbiosis) in recent years have been associated with the onset and/or progression of neurological and neuropsychiatric disorders. The purpose of this narrative review is to provide an overview of the possible involvement of the microbiota-gut-brain axis in the pathogenesis of diseases of the central nervous system, with a special focus on key issues and common misjudgments on the potential contribution of specific microorganisms.
AkbariEAsemiZDaneshvar KakhakiRBahmaniFKouchakiETamtajiOR, and others. 2016. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci8:256.
2.
AlmeidaAMitchellALBolandMForsterSCGloorGBTarkowskaA, and others. 2019. A new genomic blueprint of the human gut microbiota. Nature568(7753):499–504.
3.
AlonsoRPisaDMarinaAIMoratoERábanoARodalI, and others. 2015. Evidence for fungal infection in cerebrospinal fluid and brain tissue from patients with amyotrophic lateral sclerosis. Int J Biol Sci11(5):546–58.
AngotEBrundinP. 2009. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson’s disease. Parkinsonism Relat Disord15(suppl 3):S143–7.
6.
ArpaiaNCampbellCFanXDikiySvan der VeekenJdeRoosP, and others. 2013. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature504(7480):451–5.
7.
BaqueroFNombelaC. 2012. The microbiome as a human organ. Clin Microbiol Infect18(4):2–4.
8.
Benito-LeónJLaurenceM. 2017. The role of fungi in the etiology of multiple sclerosis. Front Neurol8:535.
9.
BererKGerdesLCekanaviciuteEJiaXXiaoLXiaZ, and others. 2017. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A114:10719–24.
10.
BorodyTLeisSCampbellJ. 2011. Fecal microbiota transplantation (FMT) in multiple sclerosis (MS). Am J Gastroenterol106:S352.
11.
BraakHBraakE. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol82(4):239–59.
12.
BranisteVAl-AsmakhMKowalCAnuarFAbbaspourATóthM, and others. 2014. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med6(263):263ra158.
13.
BrowneHForsterSAnonyeBKumarNNevilleBStaresM, and others. 2016. Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature533(7604):543–6.
14.
CammarotaGIaniroGGasbarriniA. 2014. Fecal microbiota transplantation for the treatment ofClostridium difficileinfection: a systematic review. J Clin Gastroenterol48(8):693–702.
15.
CanforaEEJockenJWBlaakEE. 2015. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol11(10):577–91.
16.
CaputiVGironMC. 2018. Microbiome-gut-brain axis and toll-like receptors in Parkinson’s disease. Int J Mol Sci19(6):1689.
17.
Castro-NallarEBendallMLPerez-LosadaMSabuncyanSSeveranceEGDickersonFB, and others. 2015. Composition, taxonomy and functional diversity of the oropharynx microbiome in individuals with schizophrenia and controls. PeerJ3:e1140.
18.
CattaneoACattaneNGalluzziSProvasiSLopizzoNFestariC, and others. 2017. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging49:60–8.
19.
CekanaviciuteEYooBBRuniaTFDebeliusJWSinghSNelsonCA, and others. 2017. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A114(40):10713–8.
20.
ChandraRHinikerAKuoYMNussbaumRLLiddleRA. 2017. α-Synuclein in gut endocrine cells and its implications for Parkinson’s disease. JCI Insight2(12):e92295.
21.
ChapmanMRRobinsonLSPinknerJSRothRHeuserJHammarM, and others. 2002. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science295(5556):851–5.
22.
ChenJChiaNKalariKRYaoJZNovotnaMSoldanMM, and others. 2016. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep6:28484.
23.
ChenSGStribinskisVRaneMJDemuthDRGozalERobertsAM, and others. 2016. Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged Fischer 344 rats and Caenorhabditis elegans. Sci Rep6:34477.
24.
CheungSGGoldenthalARUhlemannA-CMannJJMillerJMSubletteME. 2019. Systematic review of gut microbiota and major depression. Front Psychiatry10:34.
25.
ChinSMSaukJMahabamunugeJKaplanJLHohmannELKhaliliH. 2017. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease: a single-center experience. Clin Gastroenterol Hepatol15(4):597–9.
26.
ChoiIYLeePAdanyPHughesAJBellistonSDenneyDR, and others. 2018. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis. Mult Scler24(8):1029–38.
CryanJFO’MahonySM. 2011. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil23(3):187–92.
29.
DanieleSGBéraudDDavenportCChengKYinHMaguire-ZeissKA. 2015. Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders. Sci Signal8:ra45.
30.
DendrouCAFuggerLFrieseMA. 2015. Immunopathology of multiple sclerosis. Nat Rev Immunol15(9):545–58.
31.
DevosDLebouvierTLardeuxBBiraudMRouaudTPoucletH, and others. 2013. Colonic inflammation in Parkinson’s disease. Neurobiol Dis50:42–8.
32.
DickersonFBStallingsCOrigoniAKatsafanasESavageCLSchweinfurthLA, and others. 2014. Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. Prim Care Companion CNS Disord16(1):PCC.13m01579.
33.
DinanTGBorreYECryanJF. 2014. Genomics of schizophrenia: time to consider the gut microbiome?Mol Psychiatry19(12):1252–7.
34.
DonelliGVuottoCCardinesRMastrantonioP. 2012. Biofilm-growing intestinal anaerobic bacteria. FEMS Immunol Med Microbiol65(2):318–25.
35.
EllegaardKMEngelP. 2016. Beyond 16S rRNA community profiling: intra-species diversity in the gut microbiota. Front Microbiol7:1475.
36.
EnaudRVandenborghtLECoronNBazinTPrevelRSchaeverbekeT, and others. 2018. The mycobiome: a neglected component in the microbiota-gut-brain axis. Microorganisms6(1):E22.
37.
EricksonMABanksWA. 2013. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer’s disease. J Cereb Blood Flow Metab33(10):1500–13.
38.
FarhadiABananAFieldsJKeshavarzianA. 2003. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol18(5):479–97.
39.
FellnerLIrschickRSchandaKReindlMKlimaschewskiLPoeweW, and others. 2013. Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia61:349–60.
40.
ForbesJDBernsteinCNTremlettHVan DomselaarGKnoxNC. 2019. A fungal world: could the gut mycobiome be involved in neurological disease?Front Microbiol9:3249.
41.
ForsythCBShannonKMKordowerJHVoigtRMShaikhMJaglinJA, and others. 2011. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS One6(12):e28032.
42.
FreedmanSNShahiSKMangalamAK. 2018. The “gut feeling”: breaking down the role of gut microbiome in multiple sclerosis. Neurotherapeutics15(1):109–25.
43.
FurusawaYObataYFukudaSEndoTANakatoGTakahashiD, and others. 2013. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature504:446–50.
44.
GerhardtSMohajeriMH. 2018. Changes of colonic bacterial composition in Parkinson’s disease and other neurodegenerative diseases. Nutrients10(6):E708.
45.
GoodmanALKallstromGFaithJJReyesAMooreADantasG, and others. 2011. Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. Proc Natl Acad Sci U S A108(15):6252–7.
46.
GuidaFTurcoFIannottaMDe GregorioDPalumboISarnelliG, and others. 2018. Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. Brain Behav Immun67:230–45.
47.
HaghikiaAJörgSDuschaABergJManzelAWaschbischA, and others. 2015. Dietary Fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity43(4):817–29.
48.
HarachTMarungruangNDuthilleulNCheathamVMc CoyKDFrisoniG, and others. 2017. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci Rep7:41802.
49.
HouserMCTanseyMG. 2017. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?NPJ Parkinsons Dis3:3.
50.
HsiaoEYMcBrideSWHsienSSharonGHydeERMcCueT, and others. 2013. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell155(7):1451–63.
51.
HuangHXuHLuoQHeJLiMChenH, and others. 2019. Fecal microbiota transplantation to treat Parkinson’s disease with constipation: a case report. Medicine (Baltimore). 98(26):e16163.
52.
Human Microbiome Project Consortium. 2012. Structure, function and diversity of the healthy human microbiome. Nature486(7402):207–14.
53.
JangiSGandhiRCoxLMLiNvon GlehnFYanR, and others. 2016. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun7:12015.
54.
KangDWAdamsJBGregoryACBorodyTChittickLFasanoA, and others. 2017. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome5(1):10.
55.
KangDWAdamsJBColemanDMPollardELMaldonadoJMcDonough-MeansS, and others. 2019. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. Sci Rep9(1):5821.
56.
KellyJRBorreYO’BrienCPattersonEEl AidySDeaneJ, and others. 2016. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res82:109–18.
57.
KeshavarzianAGreenSJEngenPAVoigtRMNaqibAForsythCB, and others. 2015. Colonic bacterial composition in Parkinson’s disease. Mov Disord30(10):1351–60.
58.
KimCHParkJKimM. 2014. Gut microbiota-derived short-chain fatty acids, T cells, and inflammation. Immune Netw14(6):277–88.
59.
KirbyTOOchoa-RepárazJ. 2018. The gut microbiome in multiple sclerosis: a potential therapeutic avenue. Med Sci (Basel)6(3):69.
60.
KöhlerOPetersenLMorsOMortensenPBYolkenRHGasseC, and others. 2017. Infections and exposure to anti-infective agents and the risk of severe mental disorders: a nationwide study. Acta Psychiatr Scand135(2):97–105.
61.
KowalskiKMulakA. 2019. Brain-gut-microbiota axis in Alzheimer’s disease. J Neurogastroenterol Motil25(1):48–60.
62.
LagierJCKhelaifiaSAlouMTNdongoSDioneNHugonP, and others. 2016. Culture of previously uncultured members of the human gut microbiota by culturomics. Nat Microbiol1:16203.
63.
LauJTWhelanFJHerathILeeCHCollinsSMBercikP, and others. 2016. Capturing the diversity of the human gut microbiota through culture-enriched molecular profiling. Genome Med8(1):72.
64.
LeeYKMenezesJSUmesakiYMazmanianSK. 2011. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A108(1):4615–22.
65.
LiYSunHChenZXuHBuGZhengH. 2016. Implications of GABAergic neurotransmission in Alzheimer’s disease. Front Aging Neurosci8:31.
66.
LiuFLiJWuFZhengHPengQZhouH. 2019. Altered composition and function of intestinal microbiota in autism spectrum disorders: a systematic review. Transl Psychiatry9(1):43.
67.
LogsdonAFEricksonMARheaEMSalamehTSBanksWA. 2018. Gut reactions: how the blood-brain barrier connects the microbiome and the brain. Exp Biol Med (Maywood)243(2):159–65.
68.
LuczynskiPMcVey NeufeldKAOriachCSClarkeGDinanTGCryanJF. 2016. Growing up in a bubble: using germ-free animals to assess the influence of the gut microbiota on brain and behavior. Int J Neuropsychopharmacol19(8):pyw020.
69.
LundmarkKWestermarkGTOlsénAWestermarkP. 2005. Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: cross-seeding as a disease mechanism. Proc Natl Acad Sci U S A102(17):6098–102.
70.
MaciaLTanJVieiraATLeachKStanleyDLuongS, and others. 2015. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun6:6734.
71.
MaesMKuberaMLeunisJCBerkM. 2012. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord141(1):55–62.
72.
MakkawiSCamara-LemarroyCMetzL. 2018. Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS. Neurol Neuroimmunol Neuroinflamm5(4):e459.
73.
MinatoTMaedaTFujisawaYTsujiHNomotoKOhnoK, and others. 2017. Progression of Parkinson’s disease is associated with gut dysbiosis: two-year follow-up study. PLoS One12(11):e0187307.
74.
MiragliaFCollaE. 2019. Microbiome, Parkinson’s disease and molecular mimicry. Cells8(3):222.
75.
MiyakeSKimSSudaWOshimaKNakamuraMMatsuokaT, and others. 2015. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters. PLoS One10:e0137429.
76.
MiyakeSYamamuraT. 2019. Gut environmental factors and multiple sclerosis. J Neuroimmunol329:20–3.
77.
MulakABonazB. 2015. Brain-gut-microbiota axis in Parkinson’s disease. World J Gastroenterol21(37):10609–20.
78.
NavarroFLiuYRhoadsJM. 2016. Can probiotics benefit children with autism spectrum disorders?World J Gastroenterol22(46):10093–102.
79.
O’GormanCLucasRTaylorB. 2012. Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci13(9):11718–52.
80.
Ochoa-RepárazJMagoriKKasperLH. 2017. The chicken or the egg dilemma: intestinal dysbiosis in multiple sclerosis. Ann Transl Med5(6):145.
81.
OrtizGGPacheco-MoisésFPBitzer-QuinteroOKRamírez-AnguianoACFlores-AlvaradoLJRamírez-RamírezV, and others. 2013. Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol2013:708659.
82.
ParkJYChoiJLeeYLeeJELeeEHKwonHJ, and others. 2017. Metagenome analysis of bodily microbiota in a mouse model of Alzheimer disease using bacteria-derived membrane vesicles in blood. Exp Neurobiol26(6):369–79.
83.
PavlovVAChavanSSTraceyKJ. 2018. Molecular and functional neuroscience in immunity. Annu Rev Immunol36:783–812.
84.
PengWYiPYangJXuPWangYZhangZ, and others. 2018. Association of gut microbiota composition and function with a senescence-accelerated mouse model of Alzheimer’s Disease using 16S rRNA gene and metagenomic sequencing analysis. Aging (Albany NY)10(12):4054–65.
85.
PistollatoFSumalla CanoSElioIMasias VergaraMGiampieriFBattinoM. 2016. Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease. Nutr Rev74(10):624–34.
86.
PlanasRSantosRTomas-OjerPCrucianiCLutterottiAFaigleW, and others. 2018. GDP-l-fucose synthase is a CD4+ T cell-specific autoantigen in DRB3*02:02 patients with multiple sclerosis. Sci Transl Med10(462):eaat4301.
87.
RothhammerVMascanfroniIDBunseLTakenakaMCKenisonJEMayoL, and others. 2016. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med22:586–97.
88.
SampsonTRDebeliusJWThronTJanssenSShastriGGIlhanZE, and others. 2016. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell167:1469–80.e12.
89.
SancesarioGMBernardiniS. 2018. Alzheimer’s disease in the omics era. Clin Biochem59:9–16.
90.
SavignacHMCoronaGMillsHChenLSpencerJPTzortzisG, and others. 2013. Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-D-aspartate receptor subunits and D-serine. Neurochem Int63(8):756–64.
91.
SchiffrinEJBlumS. 2002. Interactions between the microbiota and the intestinal mucosa. Eur J Clin Nutr56(3):S60–4.
92.
SchmidtMJMirnicsK. 2015. Neurodevelopment, GABA system dysfunction, and schizophrenia. Neuropsychopharmacology40(1):190–206.
93.
SenderRFuchsSMiloR. 2016. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol14(8):e1002533.
94.
SeveranceEGGressittKLStallingsCRKatsafanasESchweinfurthLASavageCL, and others. 2016. Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorder. NPJ Schizophr2:16018.
95.
SeveranceEGGressittKLStallingsCRKatsafanasESchweinfurthLASavageCL, and others. 2017. Probiotic normalization of Candida albicans in schizophrenia: a randomized, placebo-controlled, longitudinal pilot study. Brain Behav Immun62:41–5.
96.
SharonGCruzNJKangDWGandalMJWangBKimYM, and others. 2019. Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell177(6):1600–18.e17.
97.
SmithPMHowittMRPanikovNMichaudMGalliniCABohlooly-YM, and others. 2013. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science341(6145):569–73.
98.
SrikanthaPMohajeriMH. 2019. The possible role of the microbiota-gut-brain-axis in autism spectrum disorder. Int J Mol Sci20(9):E2115.
99.
StewartCJAjamiNJO’BrienJLHutchinsonDSSmithDPWongMC, and others. 2018. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature562(7728):583–8.
100.
TetzGBrownSHaoYTetzV. 2018. Parkinson’s disease and bacteriophages as its overlooked contributors. Sci Rep8(1):10812.
101.
TetzGBrownSMHaoYTetzV. 2019. Type 1 diabetes: an association between autoimmunity, the dynamics of gut amyloid-producing E. coli and their phages. Sci Rep9(1):1–1.
102.
TetzGPinhoMPritzkowSMendezNSotoCTetzV. 2020. Bacterial DNA promotes Tau aggregation. Sci Rep10(1):2369.
103.
TetzGTetzV. 2018. Bacteriophages as new human viral pathogens. Microorganisms6(2):E54.
104.
TetzGVRugglesKVZhouHHeguyATsirigosATetzV. 2017. Bacteriophages as potential new mammalian pathogens. Sci Rep7(1):7043.
105.
TomasikJYolkenRHBahnSDickersonFB. 2015. Immunomodulatory effects of probiotic supplementation in schizophrenia patients: a randomized, placebo-controlled trial. Biomark Insights10:47–54.
106.
TremlettHFadroshDWFaruqiAAZhuFHartJRoalstadS, and others. 2016. Gut microbiota in early pediatric multiple sclerosis: a case–control study. Eur J Neurol23:1308–21.
107.
TükelÇ.NishimoriJHWilsonRPWinterMGKeestraAMvan PuttenJP, and others. 2010. Toll-like receptors 1 and 2 cooperatively mediate immune responses to curli, a common amyloid from enterobacterial biofilms. Cell Microbiol12(10):1495–505.
108.
TurnbaughPJGordonJI. 2009. The core gut microbiome, energy balance and obesity. J Physiol587(17):4153–8.
109.
VogtNMKerbyRLDill-McFarlandKAHardingSJMerluzziAPJohnsonSC others. 2017. Gut microbiome alterations in Alzheimer’s disease. Sci Rep7(1):13537.
110.
VogtNMRomanoKADarstBFEngelmanCDJohnsonSCCarlssonCM, and others. 2018. The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease. Alzheimers Res Ther10(1):124.
111.
VuottoCDonelliGBuckleyAChiltonC. 2018. Clostridium difficile biofilm. Adv Exp Med Biol1050:97–115.
112.
WangDHoLFaithJOnoKJanleEMLachcikPJ, and others. 2015. Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer’s disease β-amyloid oligomerization. Mol Nutr Food Res59(6):1025–40.
113.
WeghCAMGeerlingsSYKnolJRoeselersGBelzerC. 2019. Postbiotics and their potential applications in early life nutrition and beyond. Int J Mol Sci20(19):4673.
114.
YangXQianYXuSSongYXiaoQ. 2018. Longitudinal analysis of fecal microbiome and pathologic processes in a rotenone induced mice model of Parkinson’s disease. Front Aging Neurosci9:441.
115.
YolkenRHSeveranceEGSabunciyanSGressittKLChenOStallingsC, and others. 2015. Metagenomic sequencing indicates that the oropharyngeal phageome of individuals with schizophrenia differs from that of controls. Schizophr Bull41(5):1153–61.
116.
YuanTMaHLiuWNiesenDBShahNCrewsR, and others. 2016. Pomegranate’s neuroprotective effects against Alzheimer’s disease are mediated by urolithins, its ellagitannin-gut microbial derived metabolites. ACS Chem Neurosci7(1):26–33.
117.
ZhangLWangYXiayuXShiCChenWSongN, and others. 2017. Altered gut microbiota in a mouse model of Alzheimer’s disease. J Alzheimers Dis60(4):1241–57.
118.
ZhaoYLukiwWJ. 2015. Microbiome-generated amyloid and potential impact on amyloidogenesis in Alzheimer’s disease (AD). J Nat Sci1(7):e138.
119.
ZhaoYJaberVLukiwWJ. 2017. Secretory products of the human GI tract microbiome and their potential impact on Alzheimer’s disease (AD): detection of lipopolysaccharide (LPS) in AD hippocampus. Front Cell Infect Microbiol7:318.
120.
ZhuXHanYDuJLiuRJinKYiW. 2017. Microbiota-gut-brain axis and the central nervous system. Oncotarget8(32):53829–38.
121.
ZoetendalEGvon WrightAVilpponen-SalmelaTBen-AmorKAkkermansADde VosWM. 2002. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from faeces. Appl Environ Microbiol68(7):3401–7.
